Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation

Ann Hematol. 2017 Aug;96(8):1411-1413. doi: 10.1007/s00277-017-3032-8. Epub 2017 Jun 2.

Authors

Satoko Oka¹, Kazuo Ono², Masaharu Nohgawa³

Affiliations

¹ Division of Hematology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, Japan. [email protected].
² Division of Pathology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, Japan.
³ Division of Hematology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, Japan.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Anemia, Macrocytic / genetics*
Antimetabolites, Antineoplastic / therapeutic use*
Azacitidine / therapeutic use*
Biomarkers, Tumor
Bone Marrow / pathology
Chromosome Deletion
Chromosomes, Human, Pair 17 / ultrastructure
Chromosomes, Human, Pair 21 / ultrastructure
Chromosomes, Human, Pair 5 / genetics
Disease Progression
Female
Humans
In Situ Hybridization, Fluorescence
Janus Kinase 2 / genetics*
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / genetics
Leukemia, Myeloid, Acute / pathology
Multiple Myeloma / drug therapy*
Multiple Myeloma / genetics
Multiple Myeloma / pathology
Mutation, Missense*
Neoplasms, Multiple Primary / drug therapy*
Neoplasms, Multiple Primary / genetics
Neoplasms, Multiple Primary / pathology
Remission Induction
Translocation, Genetic

Substances

Antimetabolites, Antineoplastic
Biomarkers, Tumor
JAK2 protein, human
Janus Kinase 2
Azacitidine

Supplementary concepts

Chromosome 5q Deletion Syndrome